We have uncovered a new paradigm, which is that the primary tumor responsive to this therapy lost c-MYC-STAT5A/5B-PD-L1 interaction upon the treatment, and resistance is driven by STAT5A/5B. The gene discussed is STAT5A; the disease is neoplasm.